CSL Ltd (CSL) - Total Assets

Latest as of June 2025: AU$39.54 Billion AUD ≈ $27.98 Billion USD

Based on the latest financial reports, CSL Ltd (CSL) holds total assets worth AU$39.54 Billion AUD (≈ $27.98 Billion USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check CSL Ltd (CSL) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

CSL Ltd - Total Assets Trend (1993–2025)

This chart illustrates how CSL Ltd's total assets have evolved over time, based on quarterly financial data. Explore long-term investment intensity of CSL Ltd to see how much of total assets are deployed in long-term investments.

CSL Ltd - Asset Composition Analysis

Current Asset Composition (June 2025)

CSL Ltd's total assets of AU$39.54 Billion consist of 30.1% current assets and 69.9% non-current assets.

Asset Category Amount (AUD) % of Total Assets
Cash & Equivalents AU$0.00 5.5%
Accounts Receivable AU$2.88 Billion 7.3%
Inventory AU$6.47 Billion 16.4%
Property, Plant & Equipment AU$9.80 Billion 24.9%
Intangible Assets AU$8.12 Billion 20.6%
Goodwill AU$8.06 Billion 20.5%

Asset Composition Trend (1993–2025)

This chart illustrates how CSL Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CSL company net worth.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: CSL Ltd's current assets represent 30.1% of total assets in 2025, a decrease from 46.3% in 1993.
  • Cash Position: Cash and equivalents constituted 5.5% of total assets in 2025, up from 2.8% in 1993.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 40.0% of total assets, an increase from 1.0% in 1993.
  • Asset Diversification: The largest asset category is property, plant & equipment at 24.9% of total assets.

CSL Ltd Competitors by Total Assets

Key competitors of CSL Ltd based on total assets are shown below.

Company Country Total Assets
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
China CN¥7.21 Billion
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
USA $7.59 Billion
Bachem Holding AG
SW:BANB
Switzerland CHF2.11 Billion
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
China CN¥20.70 Billion
ABL Bio Inc
KQ:298380
Korea ₩280.93 Billion
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
USA $497.60 Million
Ascletis Pharma Inc
F:2VJ
Germany €2.07 Billion
ABCELLERA BIOLOGICS
F:8QQ
Germany €1.36 Billion

CSL Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 2.46 2.18 3.01
Quick Ratio 1.12 0.97 1.37
Cash Ratio 0.00 0.00 0.00
Working Capital AU$7.06 Billion AU$5.82 Billion AU$4.30 Billion

CSL Ltd - Advanced Valuation Insights

This section examines the relationship between CSL Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 3.17
Latest Market Cap to Assets Ratio 0.80
Asset Growth Rate (YoY) 3.6%
Total Assets AU$39.40 Billion
Market Capitalization $31.66 Billion USD

Valuation Analysis

Below Book Valuation: The market values CSL Ltd's assets below their book value (0.80x), which may indicate investor concerns about asset quality or future growth.

Positive Asset Growth: CSL Ltd's assets grew by 3.6% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for CSL Ltd (1993–2025)

The table below shows the annual total assets of CSL Ltd from 1993 to 2025.

Year Total Assets Change
2025-06-30 AU$39.40 Billion
≈ $27.88 Billion
+3.63%
2024-06-30 AU$38.02 Billion
≈ $26.90 Billion
-30.15%
2023-06-30 AU$54.43 Billion
≈ $38.52 Billion
+32.05%
2022-06-30 AU$41.22 Billion
≈ $29.17 Billion
+127.02%
2021-06-30 AU$18.16 Billion
≈ $12.85 Billion
+17.42%
2020-06-30 AU$15.46 Billion
≈ $10.94 Billion
+26.07%
2019-06-30 AU$12.27 Billion
≈ $8.68 Billion
+14.28%
2018-06-30 AU$10.73 Billion
≈ $7.60 Billion
+17.66%
2017-06-30 AU$9.12 Billion
≈ $6.45 Billion
+20.39%
2016-06-30 AU$7.58 Billion
≈ $5.36 Billion
+55.68%
2015-06-30 AU$4.87 Billion
≈ $3.44 Billion
-22.46%
2014-06-30 AU$6.28 Billion
≈ $4.44 Billion
+5.06%
2013-06-30 AU$5.98 Billion
≈ $4.23 Billion
-0.83%
2012-06-30 AU$6.03 Billion
≈ $4.26 Billion
+4.01%
2011-06-30 AU$5.79 Billion
≈ $4.10 Billion
+41.62%
2010-06-30 AU$4.09 Billion
≈ $2.89 Billion
-13.94%
2009-06-30 AU$4.75 Billion
≈ $3.36 Billion
+5.81%
2008-06-30 AU$4.49 Billion
≈ $3.18 Billion
+48.79%
2007-06-30 AU$3.02 Billion
≈ $2.14 Billion
+31.67%
2006-06-30 AU$2.29 Billion
≈ $1.62 Billion
+2.48%
2005-06-30 AU$2.24 Billion
≈ $1.58 Billion
-17.43%
2004-06-30 AU$2.71 Billion
≈ $1.92 Billion
+166.85%
2003-06-30 AU$1.02 Billion
≈ $718.44 Million
-22.00%
2002-06-30 AU$1.30 Billion
≈ $921.05 Million
+180.08%
2001-06-30 AU$464.77 Million
≈ $328.86 Million
+37.04%
2000-06-30 AU$339.16 Million
≈ $239.98 Million
+36.06%
1999-06-30 AU$249.27 Million
≈ $176.37 Million
+24.21%
1998-06-30 AU$200.68 Million
≈ $142.00 Million
-47.90%
1997-06-30 AU$385.18 Million
≈ $272.54 Million
+30.58%
1996-06-30 AU$294.99 Million
≈ $208.72 Million
+23.38%
1995-06-30 AU$239.09 Million
≈ $169.17 Million
-23.53%
1994-06-30 AU$312.67 Million
≈ $221.24 Million
+204.58%
1993-06-30 AU$102.66 Million
≈ $72.64 Million
--

About CSL Ltd

AU:CSL Australia Biotechnology
Market Cap
$31.66 Billion
AU$44.75 Billion AUD
Market Cap Rank
#850 Global
#16 in Australia
Share Price
AU$92.24
Change (1 day)
-0.35%
52-Week Range
AU$92.24 - AU$272.00
All Time High
AU$321.70
About

CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma produ… Read more